Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation ...

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Amgen's market standing. Stay informed and make well-considered decisions with our ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng passed away from cancer on Dec.10, ...

Machine Learning to Predict Mortality in Older Patients With Cancer: Development and External Validation of the Geriatric Cancer Scoring System Using Two Large French Cohorts Patients had squamous ...

Between 3% and 5% of colorectal cancers exhibit the KRAS G12C mutation. Credit: SewCreamStudio/Shutterstock. Amgen’s LUMAKRAS (sotorasib) and Vectibix (panitumumab ...

The Food and Drug Administration has approved Amgen sotorasib (Lumakras) with panitumumab (Vectibix) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA approvals. Calquence, in combination with chemotherapy bendamustine and ...

The U.S. Food and Drug Administration (FDA) gave Amgen (NASDAQ:AMGN) approval to use its KRASG12C inhibitor Lumakras with Vectibix for treating advanced colorectal cancer. Warning! GuruFocus has ...

Jan 16 (Reuters) - The U.S. Food and Drug Administration approved Amgen's (AMGN.O), opens new tab combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.